Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The malic acid inhibiting inflammation in ankylosing spondylitis by interfering M1 macrophage polarization.
Int Immunopharmacol
January 2025
Department of Joint Bone Disease Surgery, Changhai Hospital, Naval Medical University, 168 Changhai Road, Shanghai 200433, China. Electronic address:
Ankylosing spondylitis (AS) is a motor system immune disease with significant genetic characteristics, resulting in joint fusion, deformity, rigidity, seriously affecting the quality of life of patients. Inflammatory bowel disease (IBD), characterized by intestinal mucosal damage and inflammatory changes, the most common extra-articular manifestation of AS. Due to the limitations of the application of therapeutic drugs, it is urgent to look for new mechanisms and strategies to effectively inhibit AS inflammation is.
View Article and Find Full Text PDFPolymorphic variation of the DEFB1 gene might contribute to the development of ankylosing spondylitis: a preliminary study.
Mol Biol Rep
October 2024
Laboratorio de Líquido Sinovial, Instituto Nacional de Rehabilitación "Luis Guillermo Ibarra Ibarra", Mexico City, Mexico.
Article Synopsis
- Ankylosing spondylitis (AS) is an inflammatory disease impacting the spine and related areas, with possible extra-articular effects, and β-Defensins may influence the immune response in AS patients.* -
- The study focused on two gene variants (rs11362 and rs1800972) in Mexican AS patients, finding significant associations between certain genotypes and increased AS risk, as well as elevated inflammatory markers like CRP and ESR in specific genotype carriers.* -
- Results indicate that the DEFB1 gene is potentially crucial in the development of AS, highlighting the gene's interactions with factors such as sex.*
Determinants associated with the prescription of a first biologic therapy in patients with axial spondyloarthritis and concomitant fibromyalgia in daily practice.
Joint Bone Spine
December 2024
Rouen Université, UNIROUEN, CHU de Rouen, Department of Rheumatology, CIC-CRB 1404, 76000 Rouen, France. Electronic address:
Objectives: There is no consensus on the therapeutic strategy of rheumatologists for patients with spondyloarthritis (SpA) and concomitant fibromyalgia (FM). The main aim of this study was to identify, in a population of rheumatologists practicing in Normandy, France, the determinants associated with their decision to prescribe a first biologic DMARD (bDMARD) in patients with Spa/FM. Specific objectives were to evaluate professional prescribing practices to identify a set of criteria likely to contribute to the therapeutic decision of rheumatologists, and to validate the relevance of these criteria.
View Article and Find Full Text PDFPosture, balance and gait in axial spondyloarthritis: a case-control study.
Rheumatol Int
November 2024
Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Yıldırım Beyazıt University, Ankara City Hospital, Ankara, Türkiye.
Axial spondyloarthritis (axSpA) is a chronic inflammatory disease that primarily involves the axial skeleton but may also present with peripheral joint involvement and extra-articular involvement. The present study aims to quantitatively analyze posture, balance, and gait parameters in patients with axSpA and and assess associated factors. This cross-sectional case-control study included 51 axSpA patients (30 males, 21 females; mean age 40.
View Article and Find Full Text PDFIL-17 inhibitors in axial spondyloarthritis. An overview.
Expert Opin Biol Ther
September 2024
Centre d'Investigation Clinique, INSERM CIC-1434, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
Introduction: The therapeutic armamentarium for spondyloarthritis has expanded considerably in recent years, and there is growing evidence to support the increasing use of IL-17 inhibitors (IL-17i) in axial spondyloarthritis (axSpA).
Areas Covered: This literature review provides an update on the role of IL-17 in the pathogenesis of axSpA, efficacy and safety from clinical trials and real-life studies on the use of IL17i in axSpA. We also review the impact of extra-musculoskeletal manifestations on the decision to treat with IL17i and the efficacy of IL17i on structural progression.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!